FDA Orange Book
Generic for Visicol
Visicol contains sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Visicol is sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous. 1 company holds an active FDA approval (ANDA) for a generic version in the Orange Book.
Run it in Rivvi
Map Visicol and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Visicol products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | 0.398GM;1.102GM | Discontinued | None | 1 | None |
NDA 021097, held by SALIX PHARMACEUTICALS INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| NOVEL LABORATORIES INC | 079247 | None (No TE code listed) | December 30, 2011 | 0.398GM;1.102GM |
Questions
Is there a generic for Visicol?
Yes. The generic name for Visicol is sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous. 1 company holds an active FDA approval (ANDA) for a generic version in the Orange Book.
What is the generic name for Visicol?
The active ingredient in Visicol is sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.